Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Time to act on drug safety

Article Abstract:

The US needs an independent organization that can provide nationwide surveillance for adverse drug reactions and communicate that information quickly and effectively to physicians and the public. The Food and Drug Administration attempts to identify adverse effects of newly marketed drugs, but has few resources to follow drugs that have been on the market for a long time. In 1998, a department of only 52 people was responsible for monitoring the approximately 5,000 drugs already on the market. The drugs terfenadine and fenfluramine were withdrawn many years after they had been approved.

Author: Moore, Thomas J., Furberg, Curt D., Psaty, Bruce M.
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1998
Management, Safety and security measures, United States. Food and Drug Administration

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Thyroid storm

Article Abstract:

A study on the equivalence of four thyroid hormone preparations illustrates the dangers of accepting research money from pharmaceutical companies. The study found that Synthroid, the most commonly used thyroid hormone, was equivalent to several generic versions. However, the company that manufactures Synthroid and also funded the study harassed the researchers and tried to suppress publication of the paper. The funding contract included a clause forbidding publication if the company objected to the results and the university involved failed to support its researchers.

Author: Rennie, Drummond
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1997
Pharmaceutical industry, Ethical aspects, Academic freedom

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Stopping medical research to save money: a broken pact with researchers and patients

Article Abstract:

No adequate conclusion can be reached in a study of extended-release verapamil for treating hypertension because the sponsoring pharmaceutical company discontinued the study before it was completed. This illustrates the danger of giving sponsors the right to discontinue a study for economic reasons, as happened in this case. Other studies have shown that thiazide diuretics may be the best drug for many patients with hypertension.

Author: Rennie, Drummond, Psaty, Bruce M.
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2003
Evaluation, Cooking, Hypertension, Drug therapy, Verapamil, Cookery for hypertensives

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Drugs, Editorial
Similar abstracts:
  • Abstracts: Time to grasp the nettle. The future is yours. Are nurses losing sight of the patient?
  • Abstracts: SARS-associated coronavirus. The severe acute respiratory syndrome. Identification of a novel coronavirus in patients with severe acute respiratory syndrome
  • Abstracts: Brief interventions for alcohol problems in hospital settings. Alcohol-related health problems in general hospitals
  • Abstracts: Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. The immunopathogenesis of sepsis
  • Abstracts: Withdrawal syndrome. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.